Key Points
- OPKO Health CEO Phillip Frost bought 580,000 shares on November 19 at an average price of $1.31 for a total of $759,800, raising his direct holdings to 215,546,448 shares (about $282.4M), a 0.27% increase.
- The purchase is part of a string of recent insider buys by Frost, including 533,300 shares on November 18 at $1.27 and 150,000 shares on October 31 at $1.42, indicating continued insider accumulation.
- OPKO trades around $1.31 with a market cap of ~$1.01 billion, reports negative earnings, and carries a consensus analyst rating of "Hold" with an average price target of $2.28.
OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost bought 580,000 shares of the business's stock in a transaction dated Wednesday, November 19th. The shares were purchased at an average price of $1.31 per share, for a total transaction of $759,800.00. Following the transaction, the chief executive officer directly owned 215,546,448 shares of the company's stock, valued at approximately $282,365,846.88. This represents a 0.27% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.
Phillip Md Et Al Frost also recently made the following trade(s):
- On Tuesday, November 18th, Phillip Md Et Al Frost bought 533,300 shares of OPKO Health stock. The stock was purchased at an average cost of $1.27 per share, with a total value of $677,291.00.
- On Friday, October 31st, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.42 per share, for a total transaction of $213,000.00.
OPKO Health Price Performance
Shares of NASDAQ OPK opened at $1.31 on Thursday. The stock has a market cap of $1.01 billion, a P/E ratio of -5.24 and a beta of 1.50. OPKO Health, Inc. has a twelve month low of $1.11 and a twelve month high of $2.04. The stock has a 50 day moving average of $1.44 and a two-hundred day moving average of $1.37. The company has a current ratio of 3.41, a quick ratio of 3.02 and a debt-to-equity ratio of 0.25.
OPKO Health (NASDAQ:OPK - Get Free Report) last announced its earnings results on Wednesday, October 29th. The biotechnology company reported $0.03 EPS for the quarter, beating analysts' consensus estimates of ($0.02) by $0.05. The business had revenue of $151.67 million for the quarter, compared to analysts' expectations of $165.74 million. OPKO Health had a negative net margin of 28.10% and a negative return on equity of 13.62%. The company's quarterly revenue was down 12.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.03 EPS. On average, research analysts forecast that OPKO Health, Inc. will post -0.25 earnings per share for the current year.
Analyst Ratings Changes
OPK has been the topic of several recent research reports. Weiss Ratings restated a "sell (d-)" rating on shares of OPKO Health in a research report on Wednesday, October 8th. Zacks Research upgraded OPKO Health from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 14th. JPMorgan Chase & Co. began coverage on OPKO Health in a research note on Thursday. They set a "neutral" rating for the company. Wall Street Zen raised OPKO Health from a "strong sell" rating to a "hold" rating in a report on Saturday, November 1st. Finally, Barrington Research reissued an "outperform" rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $2.28.
Get Our Latest Report on OPKO Health
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in OPK. Oak Thistle LLC purchased a new stake in shares of OPKO Health during the 1st quarter worth approximately $26,000. Caprock Group LLC purchased a new position in OPKO Health during the 3rd quarter valued at about $26,000. GM Advisory Group LLC acquired a new position in OPKO Health during the first quarter worth about $33,000. Savant Capital LLC purchased a new stake in shares of OPKO Health in the third quarter valued at about $33,000. Finally, Cerity Partners LLC purchased a new stake in shares of OPKO Health in the first quarter valued at about $36,000. 64.63% of the stock is owned by hedge funds and other institutional investors.
About OPKO Health
(
Get Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
